Wolfgang Petritsch
YOU?
Author Swipe
View article: Tofacitinib in the treatment of ulcerative colitis
Tofacitinib in the treatment of ulcerative colitis Open
Summary Ulcerative colitis (UC) is one of the main forms of inflammatory bowel disease (IBD). Despite the widening range of drug treatment options, primary nonresponse, secondary loss of response as well as adverse events call for addition…
View article: Limited long‐term treatment persistence of first anti‐TNF therapy in 538 patients with inflammatory bowel diseases: a 20‐year real‐world study
Limited long‐term treatment persistence of first anti‐TNF therapy in 538 patients with inflammatory bowel diseases: a 20‐year real‐world study Open
Summary Background Anti‐TNF antibodies were the first biologic treatment option for patients with inflammatory bowel diseases. Aims To assess length of treatment persistence of first anti‐TNF therapy and influencing factors used in the sta…
View article: Biosimilars in der Gastroenterologie
Biosimilars in der Gastroenterologie Open
Zusammenfassung Biologika nehmen eine herausragende Rolle in der Therapie chronisch-entzündlicher Darmerkrankungen (CED) ein. Diese aus lebenden Zellen biotechnologisch hergestellten Antikörper (Ak) ermöglichen zunehmend selektive antientz…
View article: Stellenwert von Vedolizumab als Erstlinienbiologikum bei chronisch-entzündlichen Darmerkrankungen (CED)
Stellenwert von Vedolizumab als Erstlinienbiologikum bei chronisch-entzündlichen Darmerkrankungen (CED) Open
Vedolizumab (Entyvio®) ist ein darmselektiver monoklonaler IgG1-Antikörper, der zur Behandlung der Colitis ulcerosa und des Morbus Crohn zugelassen ist. Im Vergleich zu Tumornekrosefaktor Alpha (TNF-α) Inhibitoren bietet Vedolizumab bei ch…
View article: P695 Does anticoagulation treatment increase the rate of major bleeding complications in patients with IBD and venous thromboembolism?
P695 Does anticoagulation treatment increase the rate of major bleeding complications in patients with IBD and venous thromboembolism? Open
Patients with inflammatory bowel disease (IBD) are at increased risk of first and recurrent venous thromboembolism (VTE). Anticoagulation (AC) is the standard treatment of VTE, but might lead to bleeding complications. We sought to investi…
View article: The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis
The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis Open
Summary Background Faecal microbiota transplantation is an experimental approach for the treatment of patients with ulcerative colitis. Although there is growing evidence that faecal microbiota transplantation is effective in this disease,…
View article: Antibiotic-Associated Apoptotic Enterocolitis in the Absence of a Defined Pathogen: The Role of Intestinal Microbiota Depletion*
Antibiotic-Associated Apoptotic Enterocolitis in the Absence of a Defined Pathogen: The Role of Intestinal Microbiota Depletion* Open
Objective: Antibiotic therapy is a major risk factor for the development of diarrhea and colitis with varying severity. Often the origin of antibiotic-associated gastrointestinal deterioration remains elusive and no specific infectious age…
View article: The efficacy and safety of either infliximab or adalimumab in 362 patients with anti‐<scp>TNF</scp>‐α naïve Crohn's disease
The efficacy and safety of either infliximab or adalimumab in 362 patients with anti‐<span>TNF</span>‐α naïve Crohn's disease Open
Summary Background TNF α antagonists, including infliximab ( IFX ) and adalimumab ( ADA ), have revolutionised treatment for Crohn's disease. Studies comparing efficacy in patients with Crohn's disease naïve to TNF α antagonists are lackin…
View article: Diet therapy for inflammatory bowel diseases: The established and the new
Diet therapy for inflammatory bowel diseases: The established and the new Open
Although patients with inflammatory bowel diseases (IBD) have a strong interest in dietary modifications as part of their therapeutic management, dietary advice plays only a minor part in published guidelines. The scientific literature sho…
View article: P331. Endoscopic Balloon Dilation Delays the Need for Subsequent Surgery in Patients With Strictures In Crohn's Disease Even In Ileocolonic Anastomotic (ICA) Localization ?
P331. Endoscopic Balloon Dilation Delays the Need for Subsequent Surgery in Patients With Strictures In Crohn's Disease Even In Ileocolonic Anastomotic (ICA) Localization ? Open
category, respectively.At week 52, remission was achieved by 65 (38%), 42 (37%), and 9 (41%) pts treated with VDZ aged <35, 35 to 55, and >55 years, respectively.AEs occurred at similar rates across the ages (Table ).Three malignancies wer…